• 4 Best Practices That Kept A Biotech’s Clinical Trial Moving In The COVID-19 Era

    The timely enrollment and progression of clinical trials is critical for a pre-commercial biotech company, as delays can keep treatments from getting to patients and cost an organization significant money and reputation. When you throw in a worldwide pandemic, it’s a whole new ball game.

  • Can CROs Rise To The Patient Access & Recruitment Challenge?

    You have a human condition to improve and a protocol to follow. All smooth sailing from here, right? Indeed, even the most well-planned clinical trial is dead in the water if the needed patients are not accessible or willing to participate.

  • How Can We Begin To Solve Unconscious Systemic Bias In Clinical Trials?

    Halting disparities in clinical trials during the time of COVID-19 will take eradicating unconscious bias, building trust in diverse communities, dispelling long-held myths, constructing relationships, and educating patients, family members, and physicians.

  • 5 Bad Habits The Clinical Trial Community Needs To Break ASAP

    The issue of clinical trial costs, both in terms of money and time, is big, complicated, and not at all new. In this article, I will not attempt to address or solve all of the problems that contribute to these high costs, but I will highlight some continuing root causes that I believe persist needlessly.

  • 3 Essential Considerations For Running Global Clinical Trials

    In recent years, global clinical trials have become standard, and for a good reason. Expanding clinical trials across the world gives the investigational drug better opportunity to demonstrate its true impact. In this article, Dr. Roger Tell looks at three key considerations when designing a global clinical trial: selecting the most appropriate trial sites with a representative patient population, choosing to work with the right partners, and ensuring you are up to speed with local regulatory and clinical requirements.

  • Unpacking FDA’s New Guidance On Collecting Patient Experience Data

    The FDA recently released one of what is to be four new guidances providing a general overview of patient-focused drug development. This article summarizes each component of "Guidance 1: Collecting Comprehensive and Representative Input" and details how the guidance may impact sponsors of clinical trials.

  • Transformative Reflections On The Life Science World, Post-COVID-19

    The post-pandemic response has led to drastic public health changes and new ways of creating diagnostics and treatments. COVID-19 was a turning point. The pandemic exposed weaknesses in internal processes, reliance upon traditional methodologies, and leadership gaps. It demonstrated a valuable capacity to leverage innovative technologies for prioritizing patient safety, to rapidly implement creative ways of enabling healthcare providers to continue providing care, and a new framework for solving complex medical challenges.

  • Searching For Clinical Trials: How Can We Improve The Patient Experience?

    While adherence to guidance is not optimal, the bigger issue is the widespread absence of patient focus in most brief titles and brief summaries.


  • Bayesian Methodologies To Address Clinical Development Challenges For COVID-19 Drugs, Devices And Biologics

    There are numerous challenges when designing COVID-19 trials including include lack of prior data for candidate interventions/vaccines due to the novelty of the disease and the evolving standard of care as knowledge accumulates on the COVID-19 disease, and emerging evidence from completed trials. Bayesian statistical methods are very well suited to address these challenges due to their ability to adapt to knowledge that is gained during a trial.

  • SEO, UX Key To Finding – And Understanding – Clinical Trials

    According to experts, sponsors’ clinical trials websites should focus on three primary areas: patient-centric content and design, navigation and mobile friendliness.

  • Rapid Change, Real Promise: The Future Of Rare Oncology Research

    Insight on the major issues being raised in the rare oncology space today, including patient perspectives on rare cancer research, innovative trial designs, the regulatory landscape, and pending legislation that may impact how studies are conducted.

  • How Disclosure As A Service Can Reduce The Burden And Raise The Bar For Transparency

    With the help of software and services, sponsors can expand their options. Sponsors struggling to maintain compliance can do so more efficiently. Those whose goal is to overachieve can turn such aspirations into reality.

  • Successful BYOD In Any Phase

    The idea of BYOD for use in clinical trials during any phase has historically been conceptualized as a futuristic alternative, rather than what it actually is — a viable option for many clinical trials. While there has typically been hesitance among sponsors and CROs to choose a BYOD model for their study, there is an increasing number of trials that have successfully deployed this model with great results. Read more about the Advantages and Misconceptions of BYOD and what you should consider if you are deciding whether BYOD is an option for your study.

  • 505 (b)(2) vs. ANDA: How Complex Drugs Fit In

    Read how recently released draft guidance documents can provide clarity on abbreviated approval pathways and highlight priorities of the FDA to increase competition in the marketplace with a focus on speeding generic approvals, including complex generic drug products.


  • Increasing Efficiency And Expertise With A Powerful Clinical Research Platform

    A full-service CRO that helps pharmaceutical and biotechnology development firms complete clinical trials and prepare regulatory submissions to the US Food and Drug Administration (FDA) and other regulatory agencies for approval needed an EDC solution that it knew could support a wide variety of studies and study parameters. The IBM® Clinical Development solution armed them with a powerful clinical research platform that provides fully integrated advanced modules, such as medical coding and randomization, that help the organization continue to simplify clinical study processes and increase overall trial efficiency.

  • Agility And Expertise Combine To Overcome Late Stage Design Issues In Comparator Study

    Encountering unforeseen problems when sourcing a comparator for an investigational product can severely impact the success of a clinical trial. Download this case study to learn how Almac Clinical Services helped one sponsor overcome late stage design issues through successful sourcing and procurement of a suitable alternative comparator.

  • Actigraphy For Multiple Sclerosis

    Activity patterns of those with multiple sclerosis (MS) fluctuate over time according to exacerbations and remissions, and therefore represent an important marker of disease progression. Read how actigraphy can be used to to measure conventional activity, sleep, and circadian endpoints and more to assist in studies.

  • How Ramping Up Communications Helped Overcome A Next-To-Impossible Recruitment Challenge

    We knew going in that it could be the perfect recruiting nightmare with extremely complex inclusion/exclusion criteria. By letting sites set their own goals and commit to them along with assigning project coordinators that stayed close to those sites the study is off to a good start.

  • Texas Cardiology Research Department Transforms Document Access, Fuels Productivity

    What drives an established and experienced clinical research site to completely transform the way they manage regulatory and trial documentation? For South Texas Cardiovascular Consultants, PLLC (STCC) it wasn’t just about paper, it was about what paper forced us to do.

  • 6 Reasons You Don’t Use Pharmaceutical Market Research

    If you're using one of these six excuses for ignoring pharma market research, you're failing to understand barriers to success, missing the market’s perspective, and leaving assumptions unvalidated.




In this eBook, we take a close look at Real World Evidence. What is it, how is it being used, why all the hype over it, and how the use of RWE is bringing together the worlds of pharma R&D and healthcare. But more importantly, how can we best tap into the data we have available to us today to improve clinical studies and healthcare in the future. Our experts include executives from Bristol-Myers Squibb, Pfizer, the University of Southern California, and Harvard Medical School.

More Content Collections



  • How Can We Begin To Solve Unconscious Systemic Bias In Clinical Trials?

    Halting disparities in clinical trials during the time of COVID-19 will take eradicating unconscious bias, building trust in diverse communities, dispelling long-held myths, constructing relationships, and educating patients, family members, and physicians.

  • 6 Practical Ways To Increase Diversity In Clinical Trials

    Even when a certain disease is more prevalent in a particular minority population, it can still be difficult for trial investigators to reach the right individuals. As an industry — as a group of researchers dedicating our lives to improve the health of others, regardless of their race, age, gender, or disease — how can we do better?

  • Diverse Enrollment In Clinical Trials: What Do Successful Research Sites Have In Common?

    Diverse enrollment in clinical research studies is a complex issue that has multifaceted implications for clinical research sites. An understanding of the research site community’s perceived awareness and current ability to enroll these populations is lacking in the clinical trials landscape.